DHR Stock Recent News

WASHINGTON , July 16, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) ("Danaher" or the "Company"), the global life sciences and diagnostics innovator, today published its 2024 Sustainability Report which conveys the depth and scope of Danaher's sustainability program and highlights important milestones the Company achieved during the past year. "At the heart of everything we do at Danaher is our commitment to continuous improvement, and our sustainability program exemplifies this commitment," said Rainer Blair, President and Chief Executive Officer.

Predictive tools will seek to reduce leading cause of failure rates in clinical trials of oncology drugs. Integrated AI and microscopy expected to lead to better understanding of tumor structures and treatment strategies.

Ideally Suited for Satellite and Independent Labs, the new DxC 500i Analyzer Offers Flexibility, Scalability and Data Commutability with Extensive Chemistry and Immunoassay Assay Menu The New DxC 500i Analyzer Incorporates Recently Introduced DxC 500 AU Chemistry Analyzer Technology with Six Sigma Performance BREA, Calif. , July 9, 2024 /PRNewswire/ -- Beckman Coulter Diagnostics, a clinical diagnostics leader, today introduces the new DxC 500i Clinical Analyzer*, an integrated clinical chemistry and immunoassay analyzer.

Each week, Benzinga's Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks just under the surface and warrant attention.

WASHINGTON , June 24, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the second quarter 2024 on Tuesday, July 23, 2024 beginning at 8:00 a.m. ET and lasting approximately one hour.

WASHINGTON , June 19, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) ("Danaher" or the "Company"), a leading global life sciences and diagnostics innovator, today announced that Julie Sawyer Montgomery will succeed Joakim Weidemanis as Executive Vice President, Diagnostics effective as of July 1, 2024. Mr. Weidemanis will support the transition over the next three months and will retire from Danaher on September 30, 2024 after 13 years of service.

Dublin, June 19, 2024 (GLOBE NEWSWIRE) -- The "Global Flow Cytometry Market by Technology (Cell-based, Bead-Based), Product & Service (Analyzer, Sorter, Consumables (Antibodies, Assays, Kits), Software), Application (Research (Immunology, Stem Cell, Apoptosis), Clinical (Cancer)) - Forecast to 2032" report has been added to ResearchAndMarkets.com's offering. The global flow cytometry market is estimated to reach USD 10.3 billion by 2032 from USD 5.1 billion in 2024, at a CAGR of 9.2% during the forecast period of 2024 to 2032. Advancements in reagent technologies, such as fluorophore conjugation and specificity enhancement is one of the major factor uplifting the market growth. The dominance of the reagents and consumables segment among product and services factors is notable in the flow cytometry market. This segment holds sway due to continuous demand for antibodies, dyes, and other consumables essential for cell analysis. As the use of flow cytometry expands in research, clinical di

Strength in the Life Sciences segment augurs well for Danaher (DHR). The company's measures to reward its shareholders are promising.

Move reflects increasing investment in AI as driving force for innovation and productivity. Company will host Innovation Summit in December focused on AI in R&D.

Danaher (DHR) reported earnings 30 days ago. What's next for the stock?